Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 1, 1999, Pages 50-54

  Roseth A G ^a,b   Schmidt, P N ^a,b   Fagerhol, M K ^a,b  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Calprotectin; Granulocytes; Indium 111 labelled leucocytes; Irritable bowel disease

Indexed keywords

CALPROTECTIN; INDIUM 111; IOHEXOL; MESALAZINE; METRONIDAZOLE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; GRANULOCYTE; HUMAN; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; AGED; ANTIGENS, SURFACE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; GRANULOCYTES; HUMANS; INDIUM RADIOISOTOPES; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEURAL CELL ADHESION MOLECULES; TIME FACTORS;

EID: 0033013167     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365529950172835     Document Type: Article

References (24)

1. 1. Korelitz BI. An indicator of Crohn's disease activity. A need unfulfilled. J Clin Gastroenterol 1986;8:220-2.
2. 2. DeDombal FT, Softly A. IOIBD report no 1: observer variation in calculating indices of severity and activity in Crohn's disease. Gut 1987;28:474-81.
3. 3. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964;1:89-92.
4. 4. Gomes P, Du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27:92-5.
5. 111In granulocyte excretion. Digestion 1986; 33:74-9.
6. 6. Modigliani R, Mary J-Y, Simon J-F, Cortot A, Soule J-C, Gendre J-P, et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Gastroenterology 1990;98:811-8.
7. 7. Becker W, Fischbach W, Weppler M, Mosl B, Jacoby G, Börner W. Radiolabelled granulocytes in inflammatory bowel disease: diagnostic possibilities and clinical indications. Nucl Med Commun 1988;9:693-701.
8. 8. Fagerhol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I. Calprotectin (the L1 leukocyte protein). In: Smith VL, Dedman JR, editors. Stimulus response coupling: the role of intracellular calcium binding protein. Boca Raton (FL): CRC Press Inc; 1990. p. 187-210.
9. 9. Fagerhol MK. Nomenclature for proteins: is calprotein a proper name for the elusive myelomonocytic protein? J Clin Pathol Molec Pathol 1996;49:74-9.
10. 10. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. Scand J Gastroenterol 1992;27:793-8.
11. 11. Odink K, Cerletti N, Bruggen J, Clerc RG, Tarscay L, Zwadlo G, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987;330:80-2.
12. 12. Wilkinson MM, Busuttil A, Hayward C, Brock DJ, Dorin JR, van Heyningen V. Expression pattern of two related cystic fibrosis-associated calcium-binding protein in normal and abnormal tissues. J Cell Sci 1988;91:221-30.
13. 13. Wilson GB, Jahn TL, Fonseca JR. Demonstration of serum protein differences in cystic fibrosis by isoelectic focussing in thin-layer polyacrylamid gels. Clin Chim Acta 1973;49:79-85.
14. 14. Osman S, Danpure HJ. The use of 2-(18F)fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B 1992;19:183-90.
15. 15. Crama-Bohbouth GE, Arndt JW, Pena AS, Verspaget HW, Tjon A, Tham RTO, et al. Value of indium-111 granulocyte scintigraphy in the assessment of Crohn's disease of the small intestine: prospective investigation. Digestion 1988;40:227-36.
16. 16. Park RHR, McKillop JH, Duncan A, MacKenzie JF, Russell RI. Can 111Indium autologous mixed leucocyte scanning accurately assess disease extent and activity in Crohn's disease? Gut 1988; 29:821-5.
17. 17. Adeyemi EO, Hodgson HJF. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 1992; 27:139-42.
18. 18. Uchida K, Matsuse R, Tomita S, Sugi K, Saitho O, Ohshiba S. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994;27:259-64.
19. 19. Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;57:176-80.
20. 20. Løser C, Møllgaard A, Fölsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996;39:580-6.
21. 21. Thorsgaard Pedersen N, Halgreen H, Worning H. Estimation of the 3-day faecal excretion and fat concentration as a differential test of malabsortion and maldigestion. Scand J Gastroentrol 1987;22:91-6.
22. 22. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994;35:669-74.
23. 23. Rugtveit J, Nilsen EM, Bakka A, Carlsen H, Brandtzaeg P, Scott H. Cytokine profiles differ in newly recruited and resident subset of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997;112:1493-505.
24. 24. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne J-F, et al. Correlation between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 122 cases. Gut 1994;35:231-5.